ClinicalTrials.gg
CompletedNCT05436912Updated Apr 13, 2025Results posted

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

A Phase 1 interventional study of Selpercatinib in Healthy and Hepatic Impairment, sponsored by Eli Lilly and Company. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Dec 2018, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to assess how selpercatinib gets into the blood stream and how long it takes the body to remove it when administered to participants with impaired hepatic function compared to healthy participants. Information about safety and tolerability will be collected. The study will last up to about 7 weeks, inclusive of screening period.

02

Conditions studied

  • Healthy
  • Hepatic Impairment
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants of non- who are agreeable to take measures until study completion
  • Males who are capable of fathering a child must agree to use one of the following methods of contraception from the time of the dose administration through 6 months after dose administration:

    • Male sterilization, with documented confirmation of surgical success. Male subjects will be surgically sterile for at least 90 days prior to Check-in (Day -1). If documentation is not available, male subjects must follow one of the contraception methods below:
    • Male condom with spermicide, or
    • For a female partner of male study participant:
    • Intrauterine device (IUD) (hormonal IUD; eg, Mirena®). Copper IUDs are acceptable (eg, ParaGard®);
    • Established use of oral, implanted, transdermal, or hormonal method of contraception associated with inhibition of ovulation; or
    • Bilateral tubal ligation.
  • (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
  • Have normal blood pressure, pulse rate, (ECG), and blood and urine laboratory test results that are acceptable for the study

Exclusion criteria

Exclusion Criteria:

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Have or used to have health problems or laboratory test results or readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Had blood loss of more than 500 milliliters (mL) within the previous 30 days of study screening
  • Require treatment with inducers or inhibitors of cytochrome P450 (CYP) within 14 days before the first dose of study drug through the end of treatment or early termination
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    160 milligram (mg) Selpercatinib: Normal Hepatic Function

    160 mg selpercatinib administered orally to healthy participants after at least a 2-hour fast on Day 1.

    Drug: Selpercatinib

  • Experimental
    160 mg Selpercatinib: Mild Hepatic Impairment

    160 mg selpercatinib administered orally to participants with mild hepatic impairment per Child-Pugh \[CP\] classification (CP Class A, score of 5 or 6) after at least a 2-hour fast on Day 1.

    Drug: Selpercatinib

  • Experimental
    160 mg Selpercatinib: Moderate Hepatic Impairment

    160 mg selpercatinib administered orally to participants with moderate hepatic impairment per CP classification (CP Class B, score of 7 to 9) after at least a 2-hour fast on Day 1.

    Drug: Selpercatinib

  • Experimental
    160 mg Selpercatinib: Severe Hepatic Impairment

    160 mg Selpercatinib administered orally to participants with severe hepatic impairment per CP classification (CP Class C, score of 10 to 15) after at least a 2-hour fast on Day 1.

    Drug: Selpercatinib

Interventions

  • Administered orally.

    Also known as: LY3527723, LOXO-292

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib

    PK: Cmax of selpercatinib was reported.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  2. PK: Time to Reach Cmax (Tmax) of Selpercatinib

    PK: Tmax of Selpercatinib was reported.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  3. PK: Area Under the Concentration-time Curve (AUC), From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

    PK: AUC0-t was calculated using the linear trapezoidal rule for increasing and decreasing concentrations.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  4. PK: AUC Extrapolated to Infinity (AUC0-∞) of Selpercatinib

    PK: Area under the plasma concentration time curve extrapolated to infinity, calculated as AUC(0-t) + Ct/λZ, where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  5. PK: Percentage Extrapolation for AUC (%AUCextrap) of Selpercatinib

    PK: %AUCextrap of Selpercatinib was reported.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  6. PK: Apparent Terminal Elimination Rate Constant (λz) of Selpercatinib

    PK: Apparent terminal elimination rate constant, where λZ is the magnitude of the slope of the linear regression of the log concentration versus-time profile during the terminal phase.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  7. PK: Apparent Terminal Elimination Half-life (t1/2) of Selpercatinib

    PK: Apparent terminal elimination half-life (whenever possible), where t1/2 = natural log (ln)(2)/λZ.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  8. PK: Apparent Systemic Clearance (CL/F) of Selpercatinib

    CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC (0-inf), expressed in liter/hour (L/hr).

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  9. PK: Apparent Volume of Distribution During the Terminal Phase (Vd/F) of Selpercatinib

    PK: Vd/F was calculated as CL/F/λZ.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  10. PK: Mean Residence Time (MRT) of Selpercatinib

    PK: MRT represents the average time the drug (selpercatinib) stays in the body.

    Time frame: Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose

  11. Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.

    Time frame: Baseline up to Week 7

07

Results

Posted Apr 13, 2025

Participant flow

Participant flow — Overall Study
Milestone160 Milligram (mg) Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
Started12888
Received at least one dose of study drug12888
Completed12888
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib

PK: Cmax of selpercatinib was reported.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib
nanogram per milliliter (ng/mL)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib898 ± 129.81170 ± 78.0732 ± 185.6952 ± 72.3
Statistical analysis
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Mild Hepatic Impairment · t-test, 2 sided · p = 0.3601 · Geometric mean ratio: 168.9 · 90% CI 61.3 to 465.3Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Moderate Hepatic Impairment · t-test, 2 sided · p = 0.9146 · Geometric mean ratio: 92.2 · 90% CI 23.0 to 368.9Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Severe Hepatic Impairment · t-test, 2 sided · p = 0.7478 · Geometric mean ratio: 119.6 · 90% CI 43.4 to 329.3Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
PrimaryPK: Time to Reach Cmax (Tmax) of Selpercatinib

PK: Tmax of Selpercatinib was reported.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Median · hour
PK: Time to Reach Cmax (Tmax) of Selpercatinib
hour160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Time to Reach Cmax (Tmax) of Selpercatinib2.00 (1.00 to 24.00)1.53 (1.00 to 2.03)2.00 (1.00 to 24.42)1.50 (1.00 to 3.00)
PrimaryPK: Area Under the Concentration-time Curve (AUC), From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib

PK: AUC0-t was calculated using the linear trapezoidal rule for increasing and decreasing concentrations.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/ mL)
PK: Area Under the Concentration-time Curve (AUC), From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib
hour*nanogram per milliliter (h*ng/ mL)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Area Under the Concentration-time Curve (AUC), From Time 0 to the Last Observed Non-zero Concentration (AUC0-t) of Selpercatinib17700 ± 65.020200 ± 43.114600 ± 74.027100 ± 33.7
Statistical analysis
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Mild Hepatic Impairment · t-test, 2 sided · p = 0.4279 · Geometric mean ratio: 126.1 · 90% CI 74.8 to 212.8Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Moderate Hepatic Impairment · t-test, 2 sided · p = 0.8341 · Geometric mean ratio: 92.4 · 90% CI 46.4 to 183.9Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Severe Hepatic Impairment · t-test, 2 sided · p = 0.1159 · Geometric mean ratio: 169.1 · 90% CI 97.1 to 294.6Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
PrimaryPK: AUC Extrapolated to Infinity (AUC0-∞) of Selpercatinib

PK: Area under the plasma concentration time curve extrapolated to infinity, calculated as AUC(0-t) + Ct/λZ, where Ct is the last measurable concentration and λZ is the apparent terminal elimination rate constant.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/ mL)
PK: AUC Extrapolated to Infinity (AUC0-∞) of Selpercatinib
hour*nanogram per milliliter (h*ng/ mL)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic ImpairmentParticipants With Severe Hepatic Impairment
PK: AUC Extrapolated to Infinity (AUC0-∞) of Selpercatinib17700 ± 64.920200 ± 43.014700 ± 73.627300 ± 33.5
Statistical analysis
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Mild Hepatic Impairment · t-test, 2 sided · p = 0.4289 · Geometric mean ratio: 126.0 · 90% CI 74.8 to 212.4Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
  • 160 mg Selpercatinib: Normal Hepatic Function vs 160 mg Selpercatinib: Moderate Hepatic Impairment · t-test, 2 sided · p = 0.8322 · Geometric mean ratio: 92.3 · 90% CI 46.5 to 183.3Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
  • 160 mg Selpercatinib: Normal Hepatic Function vs Participants With Severe Hepatic Impairment · t-test, 2 sided · p = 0.1131 · Geometric mean ratio: 169.6 · 90% CI 97.6 to 294.6Geometric mean ratio for natural log transformed parameter (expressed as a percent) and 90% confidence interval for geometric mean ratio of natural log transformed parameter (expressed as a percent), natural log transformed back to the linear scale.
PrimaryPK: Percentage Extrapolation for AUC (%AUCextrap) of Selpercatinib

PK: %AUCextrap of Selpercatinib was reported.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Mean · percentage of (%) of AUCextrap
PK: Percentage Extrapolation for AUC (%AUCextrap) of Selpercatinib
percentage of (%) of AUCextrap160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Percentage Extrapolation for AUC (%AUCextrap) of Selpercatinib0.422 ± 0.1900.310 ± 0.1970.373 ± 0.3280.685 ± 0.379
PrimaryPK: Apparent Terminal Elimination Rate Constant (λz) of Selpercatinib

PK: Apparent terminal elimination rate constant, where λZ is the magnitude of the slope of the linear regression of the log concentration versus-time profile during the terminal phase.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · 1/hour (1/h)
PK: Apparent Terminal Elimination Rate Constant (λz) of Selpercatinib
1/hour (1/h)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Apparent Terminal Elimination Rate Constant (λz) of Selpercatinib0.0220 ± 61.40.0266 ± 39.80.0320 ± 29.00.0175 ± 28.8
PrimaryPK: Apparent Terminal Elimination Half-life (t1/2) of Selpercatinib

PK: Apparent terminal elimination half-life (whenever possible), where t1/2 = natural log (ln)(2)/λZ.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Mean · hour
PK: Apparent Terminal Elimination Half-life (t1/2) of Selpercatinib
hour160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Apparent Terminal Elimination Half-life (t1/2) of Selpercatinib36.4 ± 19.927.9 ± 12.222.4 ± 6.3041.3 ± 13.5
PrimaryPK: Apparent Systemic Clearance (CL/F) of Selpercatinib

CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC (0-inf), expressed in liter/hour (L/hr).

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · Liters per Hour (L/h)
PK: Apparent Systemic Clearance (CL/F) of Selpercatinib
Liters per Hour (L/h)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Apparent Systemic Clearance (CL/F) of Selpercatinib9.03 ± 64.97.90 ± 43.010.9 ± 73.65.87 ± 33.5
PrimaryPK: Apparent Volume of Distribution During the Terminal Phase (Vd/F) of Selpercatinib

PK: Vd/F was calculated as CL/F/λZ.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · Liter (L)
PK: Apparent Volume of Distribution During the Terminal Phase (Vd/F) of Selpercatinib
Liter (L)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Apparent Volume of Distribution During the Terminal Phase (Vd/F) of Selpercatinib411 ± 51.5297 ± 58.0340 ± 68.6336 ± 51.8
PrimaryPK: Mean Residence Time (MRT) of Selpercatinib

PK: MRT represents the average time the drug (selpercatinib) stays in the body.

Time frame:
Predose (within 30 minutes), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours postdose
Reported as:
Geometric mean · hour
PK: Mean Residence Time (MRT) of Selpercatinib
hour160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
PK: Mean Residence Time (MRT) of Selpercatinib25.5 ± 21.923.3 ± 28.924.2 ± 39.234.3 ± 20.2
PrimaryNumber of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Data presented are the number of participants who experienced SAEs considered by the investigator to be related to study drug administration. A summary of SAEs and all other non-serious Adverse Event(s) (AEs), regardless of causality, is located in the Reported Adverse Event module.

Time frame:
Baseline up to Week 7
Reported as:
Number · participants
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
participants160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration0000

Adverse events

Collected over Baseline up to Week 7. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
160 mg Selpercatinib: Normal Hepatic Function0/12 (0%)0/12 (0%)2/12 (16.7%)
160 mg Selpercatinib: Mild Hepatic Impairment0/8 (0%)0/8 (0%)5/8 (62.5%)
160 mg Selpercatinib: Moderate Hepatic Impairment0/8 (0%)0/8 (0%)0/8 (0%)
160 mg Selpercatinib: Severe Hepatic Impairment0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
Event160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic Impairment
DiarrhoeaGastrointestinal disorders0/121/80/80/8
Dry mouthGastrointestinal disorders0/121/80/80/8
Gastroenteritis viralInfections and infestations1/121/80/80/8
HyperglycaemiaMetabolism and nutrition disorders0/121/80/80/8
DizzinessNervous system disorders0/121/80/80/8
HeadacheNervous system disorders1/121/80/80/8
SomnolenceNervous system disorders0/121/80/80/8
Pain in extremityMusculoskeletal and connective tissue disorders1/120/80/80/8

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic ImpairmentTotal
Mean54 ± 5.659 ± 4.557 ± 9.053 ± 4.756 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic ImpairmentTotal
Female646622
Male642214
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic ImpairmentTotal
Hispanic or Latino913619
Not Hispanic or Latino375217
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic ImpairmentTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American12014
White1168732
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)160 mg Selpercatinib: Normal Hepatic Function160 mg Selpercatinib: Mild Hepatic Impairment160 mg Selpercatinib: Moderate Hepatic Impairment160 mg Selpercatinib: Severe Hepatic ImpairmentTotal
United States1288836
08

Study locations

7 sites
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • National Institute of Clinical Research
    Monterey Park, California 91754, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • The Texas Liver Institute
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Oct 2019, 9 months.

Results were first posted in Apr 2025, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Jun 29, 2022
StartActual
Dec 10, 2018
Primary completionActual
Oct 4, 2019
CompletionActual
Oct 30, 2019
Results first posted
Apr 13, 2025
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05436912
Collaborators
Loxo Oncology, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Dec 10, 2018
Primary completion
Oct 4, 2019
Completion
Oct 30, 2019
Results posted
Apr 13, 2025
Last update
Apr 13, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion